Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers

Reviewed 28 sourcesPublished by PepVault

Ozempic, Wegovy and NAION: what the labels say as of November 2026, every large study with its absolute risk, the trial data, and what tirzepatide shows.

White-bearded man in navy and grey does a seated side stretch on a mat on a sunny deck
Last reviewed
Sources
28
Questions
9
Compounds
2

The short answer

Semaglutide, the drug in Ozempic and Wegovy, is linked to NAION, a sudden loss of blood flow to the optic nerve, but the risk is small. Europe's regulator lists it as a very rare side effect: about one extra case per 10,000 people treated for a year. The large studies find roughly double a low starting risk; the randomised trials found no clear rise.

Every number checked at its primary source · · 28 sources · How we research

Evidence: Observational studies of several million people, mostly with type 2 diabetes, plus pooled randomised trials with few cases; Europe lists NAION as a very rare side effect of semaglutide, and no study proves the drug causes it.

White-bearded man in navy and grey does a seated side stretch on a mat on a sunny deck

What is NAION?

NAION, short for non-arteritic anterior ischemic optic neuropathy, is a small stroke of the optic nerve, the cable that carries sight from the eye to the brain. The blood flow to the front of the nerve, where it leaves the eye, drops for a while, and the nerve fibres there are damaged. It usually shows up as sudden, painless loss of vision in one eye, often noticed on waking24. The most common pattern is a missing upper or lower half of the view in that eye25.

It was a known condition long before GLP-1 drugs. A Mayo Clinic count in one Minnesota county, 1990 to 2016, found about 4 new cases per 100,000 people a year, and about 10 per 100,000 among people aged 50 or older; the median age at diagnosis was 6528. The known risk factors are high blood pressure, diabetes, blood pressure that falls low at night, and a small, crowded optic disc, the spot where the nerve enters the eye24. There is no proven treatment for it24.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's side-effect log keeps any symptom you type with its date, a severity from minimal to very severe and your notes, beside the compound, so you can show the eye doctor when a change began.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Does Ozempic cause NAION, according to the regulators?

Europe says yes, as a very rare side effect. On June 6, 2025, the European Medicines Agency's safety committee concluded that NAION is a side effect of semaglutide (Ozempic, Rybelsus and Wegovy) with a frequency of "very rare", up to 1 in 10,000 people. Large population studies in adults with type 2 diabetes showed about twice the risk, about one additional case per 10,000 person-years (one person on the drug for one year), and trials pointed to a slightly higher risk than placebo17.

The European product information now says there is no known time window for when NAION may develop after starting, that sudden vision loss should lead to an eye examination, and that semaglutide is stopped if NAION is confirmed18.

The US labels do not list it. As of November 2026, the FDA labels for Ozempic (DailyMed version 20, published June 10, 2026), Wegovy (version 19, June 30, 2026), Mounjaro and Zepbound (both version 40, September 2, 2026) carry no NAION or optic nerve warning; their eye warning is about diabetic retinopathy19202122.

In 2026 the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology wrote that many studies report a small possible increase, some find none, the overall risk stays low, and starting, continuing or stopping is a shared decision between patient and care team16.

How big is the NAION risk on a GLP-1, in real numbers?

Small in absolute terms. An observational study follows people in ordinary care, so the groups can differ in ways researchers cannot fully adjust for; a hazard ratio (HR) or risk ratio (RR) of 2 means about twice the rate.

StudyWhoOn the drugComparison groupRelative risk
Hathaway 2024, US1One specialist eye clinic, type 2 diabetes: 194 vs 5168.9% over 3 years1.8%HR 4.28
Hathaway 2024, same clinic1Overweight or obesity: 361 vs 6186.7% over 3 years0.8%HR 7.64
Grauslund 2024, Denmark2424,152 with type 2 diabetes2.3 per 10,000 a year0.9 per 10,000 a yearHR 2.19
Simonsen 2025, Denmark and Norway361,377 on semaglutide vs SGLT-2 inhibitors2.2 and 2.9 per 10,000 a year1.2 and 0.9HR 2.81
Cai 2025, 14 US databases4810,390 new semaglutide users1.5 per 10,000 a yearNo significant difference vs three diabetes drugs (broad definition)HR 1.23 to 1.44
Wang 2025, US779,699 on semaglutide or tirzepatide vs 79,6990.04% over 2 years0.02%HR 1.76
Heberer 2026, US veterans811,478 vs 90,883 on SGLT-2 inhibitors12.3 per 10,000 a year6.7 per 10,000 a yearHR 2.33
Noh 2026, UK9106,858 starting any GLP-1 drug vs 416,369 on DPP-4 inhibitors1.9 per 10,000 in year one0.7RR 2.56
Ueda 2026, Sweden10107,518 vs 185,898 on SGLT-2 inhibitors0.12% over 5 years0.07%RR 1.69, not significant
Reynolds 2026, US, ages 18 to 6511New users vs SGLT-2 or DPP-4 inhibitors8.5 and 7.8 per 10,000 over 18 months5.5 and 4.23.0 and 3.6 more per 10,000 (absolute)

The Mass Eye and Ear study started the headlines, and its percentages are far higher because every patient had already been sent to a specialist eye clinic; it counted 17 cases against 6 in diabetes and 20 against 3 in the weight group1. By our subtraction from the table, the drug adds about one to six cases per 10,000 people a year in the large studies. Reynolds put it as a number needed to harm: about 3,333 people treated for 18 months for one extra case, compared with an SGLT-2 inhibitor11.

What did the randomised trials find?

Very few cases, and no clear rise. A randomised trial assigns the drug or a placebo by chance, which removes most of the differences that cloud the record studies, but NAION is so rare that even big trials see only a handful.

  • All Novo Nordisk placebo-controlled trials of semaglutide and liraglutide, pooled: 96,829 people; three confirmed cases on a GLP-1 drug (about 3 per 100,000 person-years) and five in four people on placebo (about 6 per 100,000). Three of the six authors work for Novo Nordisk12.
  • 78 semaglutide trials (73,640 people): an odds ratio of 3.92 for NAION, with a range so wide (1.02 to 15.02) that the authors called the evidence insufficient13.
  • A 2026 meta-analysis by indication: 5 cases against 1 in diabetes trials and 4 against 1 in weight-loss trials, neither a significant rise14.

Pooling the record studies gives about two and a half times the risk (1.6 million people, RR 2.52) in one 2026 analysis15, and no consistent increase, at low to very low certainty, in another26.

Why do the NAION studies disagree?

Mostly because people who get semaglutide differ from those who get the comparison drug. Diabetes itself raises NAION risk, and people prescribed a GLP-1 drug often have harder-to-control diabetes. In Sweden the 5-year risk ratio fell from 1.69 to 1.23 when the analysis kept only people already on metformin, a way to compare people at a similar stage, and the authors judged the rise may reflect that difference10.

  • The comparison drug matters. Against empagliflozin, sitagliptin or glipizide, the 14-database study found no significant difference by its broad definition4.
  • Codes are blunt. Some records have no specific NAION code, so studies count all ischemic optic neuropathy instead11.
  • The timing does not line up. The UK excess came mostly in the first 6 months9, another study saw none in year one and a rise from year two6, and in Denmark the median time to NAION was 22 months2.

How semaglutide would cause it is not known. One clue: in the UK the excess was larger in people whose HbA1c, the three-month blood sugar average, fell by 1 point or more9.

Is NAION a risk on Wegovy for weight loss, or on Mounjaro and Zepbound?

For weight loss, the signal is weaker than in diabetes. Outside the single specialist clinic1, the multinational study found no rise in people with obesity alone5, and the 2026 meta-analysis found no significant rise in the weight-loss record studies (hazard ratio 1.57, range 0.69 to 3.59) or trials14. The European review's numbers come from adults with type 2 diabetes17.

For tirzepatide, the data are thin. The one large study that included it pooled it with semaglutide: 0.04% against 0.02% over two years in type 2 diabetes7. Neither the US Mounjaro and Zepbound labels2122 nor the European Mounjaro label27 lists NAION; tirzepatide has simply been studied less.

Who has a higher risk of NAION on a GLP-1?

Men and people over 50, in a US analysis of insured adults aged 18 to 65: the extra risk was largest in men, people over 50 and those with heart disease or an earlier eye condition, and minimal in women and under 5011. The UK study also found it higher in men and smokers, but, unlike the US one, in people under 50 too9.

Is diabetic retinopathy the same risk as NAION?

No, it is a separate one, and it is the eye warning that sits on every US label. Diabetic retinopathy is damage to the small blood vessels of the retina, the light-sensing layer at the back of the eye, from years of high blood sugar. When blood sugar falls quickly, existing retinopathy can get worse for a while1921.

Trial or labelWhoOn the drugOn placebo
SUSTAIN-6, 2 years23193,297 adults with type 2 diabetes and high heart risk3.0% had retinopathy complications1.8%
SUSTAIN-6, with retinopathy at the start19Same trial8.2%5.2%
SUSTAIN-6, no known retinopathy19Same trial0.7%0.4%
Wegovy weight trial in type 2 diabetes20Adults with type 2 diabetes and a BMI of 27 or more4% reported retinopathy2.7%

Complications in SUSTAIN-6 meant bleeding inside the eye, blindness, or a need for laser or injection treatment23. The Mounjaro and Zepbound labels carry a retinopathy warning too, and every label asks that people with retinopathy be monitored19202122.

What should you do about your eyes on a GLP-1?

Know your starting point, and act quickly on a sudden change181920:

  1. Before you start, tell your prescriber about any past NAION or optic nerve problem in either eye, and any diabetic eye disease.
  2. If you have diabetic retinopathy, keep your regular eye checks through the dose climb; the labels ask for monitoring.
  3. If your sight changes, cover one eye at a time to learn which eye it is, and note what is missing (a half, a patch, a blur) and when you noticed it.
  4. At the visit, name the medicine, your dose and the date you started.

When to get help A sudden loss of vision, a dark or grey patch, or eyesight that gets worse over hours or days is a reason to be seen by an eye doctor or an emergency service the same day1718.

PepVault's side-effect log keeps any symptom you type with its date, a severity from minimal to very severe and your notes, beside the compound, so you can show the eye doctor when a change began. Log it in PepVault

Track it in the app

Sources

  1. Hathaway JT et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739. PubMed 38958939
  2. Grauslund J et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97. PubMed 39696569
  3. Simonsen E et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103. PubMed 40098249
  4. Cai CX et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025;143(4):304-314. PubMed 39976940
  5. Chou CC et al. Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study. Ophthalmology. 2025;132(4):381-388. PubMed 39491755
  6. Hsu AY et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes. JAMA Ophthalmol. 2025;143(5):400-407. PubMed 40146102
  7. Wang L et al. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327. PubMed 40788646
  8. Heberer K et al. New-onset nonarteritic anterior ischemic optic neuropathy and initiators of semaglutide in US veterans with type 2 diabetes. JAMA Ophthalmol. 2026;144(3):259-264. PubMed 41678180
  9. Noh Y et al. Glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes. Diabetes Care. 2026;49(5):763-771. PubMed 41701611
  10. Ueda P et al. Glucagon-like peptide-1 receptor agonists and risk for anterior ischemic optic neuropathy: a nationwide cohort study. Ann Intern Med. 2026;179(9):1232-1243. PubMed 42441962
  11. Reynolds KR et al. Glucagon-like peptide-1 receptor agonists and risk for ischemic optic neuropathy: a target trial emulation. Ann Intern Med. 2026;179(9):1244-1253. PubMed 42441967
  12. Vilsbøll T et al. Non-arteritic anterior ischaemic optic neuropathy incidence in placebo-controlled clinical trials of liraglutide or semaglutide. Br J Ophthalmol. 2026. PubMed 42049287
  13. Natividade GR et al. Ocular adverse events with semaglutide: a systematic review and meta-analysis. JAMA Ophthalmol. 2025;143(9):759-768. PubMed 40810985
  14. Liu Z et al. Rate and risk of nonarteritic anterior ischemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis. Ophthalmology. 2026;133(5):589-598. PubMed 41475544
  15. Dhivagaran T et al. Glucagon-like peptide-1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy: systematic review and meta-analysis. Neurology. 2026;106(10):e214864. PubMed 42060879
  16. DeParis SW et al. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: a consensus statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8):1029-1035. PubMed 42132708
  17. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. Published June 6, 2025. ema.europa.eu
  18. European Medicines Agency. Ozempic: EPAR product information (sections 4.4 and 4.8), read November 20, 2026. ema.europa.eu
  19. OZEMPIC (semaglutide) injection, US prescribing information. DailyMed, set ID adec4fd2-6858-4c99-91d4-531f5f2a2d79, version 20, updated June 1, 2026, published June 10, 2026. dailymed.nlm.nih.gov
  20. WEGOVY (semaglutide) injection and tablets, US prescribing information. DailyMed, set ID ee06186f-2aa3-4990-a760-757579d8f77b, version 19, updated June 18, 2026, published June 30, 2026. dailymed.nlm.nih.gov
  21. MOUNJARO (tirzepatide) injection, US prescribing information. DailyMed, set ID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, version 40, updated August 27, 2026, published September 2, 2026. dailymed.nlm.nih.gov
  22. ZEPBOUND (tirzepatide) injection, US prescribing information. DailyMed, set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, updated August 28, 2026, published September 2, 2026. dailymed.nlm.nih.gov
  23. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PubMed 27633186
  24. Desai N et al. Nonarteritic anterior ischemic optic neuropathy. J Clin Hypertens (Greenwich). 2005;7(2):130-133. PubMed 15722660
  25. Hattenhauer MG et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123(1):103-107. PubMed 9186104
  26. Abdelaal A et al. Semaglutide and the risk of nonarteritic ischemic optic neuropathy: a systematic review and certainty of evidence meta-analysis. Ophthalmology. 2026;133(6):799-810. PubMed 41692115
  27. European Medicines Agency. Mounjaro: EPAR product information (sections 4.4 and 4.8), read November 20, 2026. ema.europa.eu
  28. Foster RC et al. Reexamining the incidence of nonarteritic anterior ischemic optic neuropathy: a Rochester Epidemiology Project study. J Neuroophthalmol. 2024;44(3):337-341. PubMed 38358828

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo